2018 年第 10 期 第 13 卷

贝伐珠单抗联合替莫唑胺治疗复发恶性脑胶质瘤的临床效果及安全性

Efficacy and safety of bevacizumab combined with temozolomide in treatment of recurrent malignant glioma

作者：王飞李春红

英文作者：

单位：250031济南，山东省医学科学院附属医院神经外科（王飞）；250062济南，山东省职业卫生与职业病防治研究院康复科（李春红）

英文单位：

关键词：复发恶性脑胶质瘤；贝伐珠单抗；替莫唑胺

英文关键词：

• 摘要：

• 【摘要】目的    探讨贝伐珠单抗联合替莫唑胺治疗复发恶性脑胶质瘤的临床效果及安全性。方法    选取山东省医学科学院附属医院2013年1月至2017年10月收治的复发恶性脑胶质瘤患者62例。采用随机数字表法将所选取的研究对象分为观察组和对照组，每组31例。对照组患者单纯使用替莫唑胺进行治疗；观察组患者使用贝伐珠单抗联合替莫唑胺进行治疗。治疗4周后评价疗效。对比2组治疗效果及不良反应情况。结果    观察组疾病缓解率和疾病控制率均明显高于对照组［48.4%（15/31）比19.4%（6/31）、77.4%（24/31）比54.8%（17/31）］，差异均有统计学意义（均P＜0.05）。2组患者的不良反应均以骨髓抑制和胃肠道反应为主，观察组与对照组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论    贝伐珠单抗与替莫唑胺联合治疗复发恶性脑胶质瘤能够有效提高临床效果，且安全性相对较高。

• 【Abstract】Objective    To investigate the efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant glioma. Methods    A total of 62 patients with recurrent malignant glioma admitted from January 2013 to October 2017 in Affiliated Hospital of Shandong Academy of Medical Sciences were randomly divided into observation group and control group, with 31 cases in each group. The control group was treated with temozolomide; the observation group was treated with bevacizumab plus temozolomide. Therapeutic effect and adverse reactions were analyzed after 4 weeks of treatment. Results    Disease remission rate and disease control rate in the observation group were significantly higher than those in the control group［48.4%（15/31） vs 19.4%（6/31）, 77.4%（24/31） vs 54.8%（17/31）］（P＜0.05）. Myelosuppression and gastrointestinal discomforts were the main adverse reactions. The incidence rate of adverse reactions showed no significant difference between the observation group and control group（P＞0.05）. Conclusion    Bevacizumab combined with temozolomide is safe and effective in the treatment of recurrent malignant glioma.